Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
Bio-Path Holdings, Inc. (BPTH)
Last bio-path holdings, inc. earnings: 11/14 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
biopathholdings.com
Company Research
Source: GlobeNewswire
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML) Supportive Safety and Efficacy Data from Two Assets Validate Potential of DNAbilize® Platform Technology to Treat Most Vulnerable Cancer Patients HOUSTON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the Company’s ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia (AML). “These positive responses mark a significant milestone f
Show less
Read more
Impact Snapshot
Event Time:
BPTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPTH alerts
High impacting Bio-Path Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
BPTH
News
- Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024GlobeNewswire
- Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bio-Path files to sell 17.76M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
BPTH
Earnings
- 8/14/24 - Beat
BPTH
Sec Filings
- 11/13/24 - Form SC
- 11/6/24 - Form SC
- 10/28/24 - Form ARS
- BPTH's page on the SEC website